Form 4: UNITED THERAPEUTICS Executive Sells Shares
Insider Transaction (Form 4)
Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on July 16, 2026.
Summary
- Option exercise/conversion: acquired 8,300 Common Stock at $146.03 ($1,212,049) on July 16, 2026; holds 53,472 after (Direct).
- Open-market sale: disposed of 600 Common Stock at $527.60 ($316,557) on July 16, 2026; holds 52,872 after (Direct).
- Open-market sale: disposed of 120 Common Stock at $529.81 ($63,577) on July 16, 2026; holds 52,752 after (Direct).
- Open-market sale: disposed of 861 Common Stock at $531.97 ($458,025) on July 16, 2026; holds 51,891 after (Direct).
- Open-market sale: disposed of 800 Common Stock at $532.94 ($426,352) on July 16, 2026; holds 51,091 after (Direct).
- Open-market sale: disposed of 3,279 Common Stock at $534.21 ($1,751,679) on July 16, 2026; holds 47,812 after (Direct).
- Open-market sale: disposed of 1,041 Common Stock at $535.88 ($557,851) on July 16, 2026; holds 46,771 after (Direct).
- Open-market sale: disposed of 1,519 Common Stock at $534.99 ($812,648) on July 16, 2026; holds 45,252 after (Direct).
- Open-market sale: disposed of 80 Common Stock at $536.85 ($42,948) on July 16, 2026; holds 45,172 after (Direct).
- Option exercise/conversion: disposed of 8,300 Stock Option on July 16, 2026; holds 80,740 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,429,638 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul A Mahon — Officer (EVP & GENERAL COUNSEL)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-16 | Option exercise/conversion | Common Stock | 8,300 | $146 | $1.2M | 53,472 |
| 2026-07-16 | Open-market sale | Common Stock | 600 | $528 | $316.6K | 52,872 |
| 2026-07-16 | Open-market sale | Common Stock | 120 | $530 | $63.6K | 52,752 |
| 2026-07-16 | Open-market sale | Common Stock | 861 | $532 | $458.0K | 51,891 |
| 2026-07-16 | Open-market sale | Common Stock | 800 | $533 | $426.4K | 51,091 |
| 2026-07-16 | Open-market sale | Common Stock | 3,279 | $534 | $1.8M | 47,812 |
| 2026-07-16 | Open-market sale | Common Stock | 1,041 | $536 | $557.9K | 46,771 |
| 2026-07-16 | Open-market sale | Common Stock | 1,519 | $535 | $812.6K | 45,252 |
| 2026-07-16 | Open-market sale | Common Stock | 80 | $537 | $42.9K | 45,172 |
| 2026-07-16 | Option exercise/conversion | Stock Option | 8,300 | — | — | 80,740 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-16 | Option exercise/conversion (8,300 shares) |
| 2026-07-16 | Open-market sale (600 shares) |
| 2026-07-16 | Open-market sale (120 shares) |
| 2026-07-16 | Open-market sale (861 shares) |
| 2026-07-16 | Open-market sale (800 shares) |
| 2026-07-16 | Open-market sale (3,279 shares) |
| 2026-07-16 | Open-market sale (1,041 shares) |
| 2026-07-16 | Open-market sale (1,519 shares) |
| 2026-07-16 | Open-market sale (80 shares) |
| 2026-07-16 | Option exercise/conversion (8,300 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Paul A Mahon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.